Ashland will buy International Specialty Products (ISP) in a deal designed to expand it's business in less cyclical, high-growth markets such as pharmaceuticals and personal care.
From July the EC will require that gelatin used in parenteral drugs is sourced from countries in World Organisation for Animal Health's (OIE) lowest risk categories for bovine spongiform encephalopathy (BSE).
German transdermal drug developer, Labtec, has opened what it claims is Europe’s most modern manufacturing facility for the production of transdermal drug delivery systems (TDS) and oral dispersible films (ODF) using its proprietary RapidFilm technology.
Serina Therapeutics has developed a new way of synthesizing polyoxazoline (POZ) polymers for drug delivery applications that, it claims, is free of the drawbacks that have hampered previous production methods.
SAFC, the custom manufacturing and business services wing of Sigma Aldritch, has announced a licensing agreement with biotech company, Agilent Technologies, for the sale of its nucleic acids synthesis products and technologies.
Californian biotech tool manufacturer Life Technologies has teamed with German contract research organisation (CRO) ProBiogen to release a range of royalty-free Gibco Freedom Cell Line Development Kits.
Pharmaceutical intermediate sales helped Codexis in Q1 but the US biocatalysis specialist still posted a net loss for the quarter on higher R&D spending
Quality issues slowed first quarter revenue growth at Teva but, with one plant resuming shipping and another awaiting re-inspection, sales are expected to pick up.
Chemicals supplier Aceto Corp has its sights set on opportunities in the generic drug sector after soaring active pharmaceutical ingredient (API) and intermediates sales helped it to a strong set of quarterly financials.
Carbogen Amcis’s Indian plant has met industrial standards for the containment and handling of highly potent active pharmaceutical ingredients (HPAPI).
Albany Molecular Research (AMRI) posted a modest net loss on costs and restructuring charges, but saw revenue grow considerably in the first quarter thanks to contracting business and royalties.
The second draft of Excipact, a set of certification standards for drug excipient producers being developed by the EFCG, FECC, IPEC and PQD, has been sent to industry stakeholders for consultation.
US-based vaccine specialist, Caliber Biotherapeutics, has opened the world’s largest modular, plant-made pharmaceutical manufacturing facility at its headquarters in Bryan, Texas.
US-based tissue regeneration specialist, Organogensis, has broken ground on the construction of the world’s largest automated living cell manufacturing plant in Canton, Massachusetts.
Continuous manufacturing offers significant advantages for drug production in terms of quality and efficiency, but more research and regulatory input is needed to help the pharmaceutical sector reap the benefits according to ISP.
Univar has announced plans to ramp up capacity for medicinal white oils, predicting that increased regulatory focus on supply chain integrity will drive drug industry demand.
Nano Terra, a surface engineering and nanotechnology company based in Brighton Massachusetts, US, has struck a deal to acquire neighbouring drug developer, Surface Logix.
US drugmaker Amgen has acquired Brazilian manufacturer Bergamo in a bid to improve its access to ‘one of the fastest growing pharmaceutical markets in the world.”
Next month the United Nations Conference on Trade and Development (UNCTAD) will organise a meeting to discuss ways of encouraging the production of pharmaceutical in Africa.
Cytovance Biologics, the US-based biopharmaceutical contract manufacturer (CMO), has secured a growth equity investment from Connecticut, US-based private investors, Great Point Partners.
SOCMA and the EFCG want the US FDA to make inspection of overseas API manufacturing sites mandatory, with the facilities paying for the costs themselves.
Swiss pharmaceutical ingredient maker Helsinn says its new cytotoxic API production plant will be operational for laboratory-scale projects early next year.
Thermo Fisher Scientific has launched a predictive assay that, it claims, can assess a drug candidate’s potential to cause liver damage earlier than traditional methods.
CSM GlobalPharma has announced plans to invest $65m in a manufacturing facility in Kigali, Rwanda in collaboration with the Rwandan Development Board (RDB).
Charles River Laboratories (CRL) said it will distribute several Pfizer-developed R&D models, in a deal that continues the US CRO’s efforts to expand its lab animals business.
